TScan Therapeutics TCRX 深 滬
等待開盤 09-24 09:30:00 美东时间
0.364
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.364
- 總市值 2467.16万
- 52周最高 2.57
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.2902
- 委 比 0.00%
- 總股本 6777.93万
- 歷史最高 14.71
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.2902
- 每 手 1
- 風險率 0.42%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 多家大行齐上调Robinhood目标价！最高看至150美元；安进股价大跌后评级遭下调
今日重点评级关注：Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.3美元升至8.45美元；摩根大通：维持Vera Therapeutics"超配"评级，目标价从76美元升至83美元
09-09 15:36
美股大行评级 | 大行齐上调AI应用股目标价！Adobe、CRWD等获看好，慧与科技绩后现多空分歧
今日重点评级关注：BTIG：维持Climb Bio"买入"评级，目标价从20美元升至32美元；巴克莱：维持Alpha Tau Medical"超配"评级，目标价从17美元升至30美元
09-04 12:30
TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction
TScan Therapeutics Inc. (NASDAQ:TCRX) on Wednesday announced a major corporate reorganization to prioritize its in vivo solid tumor pipeline, prompting a workforce reduction of approximately 75%. The clinical-stage biotechnology company is shifting capital toward its lead oncology programs while pau...
09-02 23:36
TScan Therapeutics shares are trading lower after the company announced it paused further enrollment in the Phase 3 ALLOHA-2 study of TSC-101 due to insufficient capital needed to complete the trial. Also, the company will reduce its workforce by 75%.
TScan Therapeutics shares are trading lower after the company announced it paused further enrollment in the Phase 3 ALLOHA-2 study of TSC-101 due to insufficient capital needed to complete the trial. Also, the company will reduce its workforce by 75%.
09-02 20:53
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
TScan Therapeutics announced strategic reorganization to focus on its in vivo solid tumor program, advancing two TCR-T candidates to IND studies with Phase 1 development planned for Q4 2027. The company paused its Phase 3 ALLOHA-2™ study of TSC-101 due to capital constraints, while Cohort C of the Phase 1 ALLOHA™ study showed 100% complete donor chimerism in 13 patients. TScan reduced its workforce by ~75% to concentrate resources on solid tumors...
09-02 11:00
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
HC Wainwright & Co. Reiterates Buy on TScan Therapeutics, Maintains $7 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $7 price target.
08-12 23:25
TScan Therapeutics Q2 EPS $(0.23) Misses $(0.21) Estimate, Sales $1.051M Miss $1.667M Estimate
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.21) by 9.52 percent. This is a 17.86 percent increase over losses of $(0.28) per share from the same period last year. The company reported quarterly sales of $1.051 mil...
08-12 19:10
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
TScan Therapeutics reported initiating its Phase 3 ALLOHA-2™ trial for TSC-101 in heme malignancies, with first patient dosed, and expects topline data mid-2028. Positive Cohort C data from the Phase 1 ALLOHA™ study validates its commercial manufacturing process, showing a 90% success rate and meaningful clinical benefit for patients. The company also announced collaborations to enhance manufacturing scalability and plans to expand its heme progr...
08-12 11:00
TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
TScan Therapeutics announced the first patient dosed in its pivotal Phase 3 ALLOHA-2 trial evaluating TSC-101 for preventing relapse in AML and MDS patients post-allo-HCT. The trial aims to assess relapse-free survival, with enrollment ongoing across the U.S., targeting a mid-2028 data readout. The company highlighted strong early results from Cohort C and expressed confidence in TSC-101's potential to improve outcomes.
07-29 11:00
